| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-09-25 | Crohn's Disease | Enterome Bioscience (France) | Autoimmune diseases - Inflammatory diseases - Digestive diseases | ||
| 2016-09-24 | ALN-GO1 | primary hyperoxaluria type 1 (PH1) | 1-2 | Alnylam Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases |
| 2016-09-23 | Zykadia® - LDK378 (ceritinib) | patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) | 3 | Novartis (Switzerland) | Cancer - Oncology |
| 2016-09-23 | ROR?t inverse agonists | preclinical | Genfit (France) | Immunological diseases | |
| 2016-09-22 | ISIS-APO(a) Rx, now IONIS-APO(a) Rx | high lipoprotein(a), or Lp(a) | 1 | Isis Pharmaceuticals, now Ionis Pharmaceuticals (USA - CA) Akcea Therapeutics (USA - CA) | Cardiovascular diseases - Metabolic diseases |
| 2016-09-21 | autologous CD34+ haematopoietic stem cells transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene | adenosine deaminase deficient severe combined immunodeficiency (ADA-SCID) | Orchard Therapeutics (UK) | Rare diseases - Genetic diseases | |
| 2016-09-21 | GS-5745 | ulcerative colitis | 2-3 | Gilead Sciences (USA - CA) | Autoimmune diseases – Inflammatory diseases - Digestive diseases |
| 2016-09-21 | CD201 | multi-drug resistant (MDR) bacterial infections, including those caused by MCR-1 resistant pathogens | Cidara Therapeutics (USA - CA) | Infectious diseases | |
| 2016-09-20 | BioChaperone® Combo | type 2 diabetes | 1b | Adocia (France) | Metabolic diseases |
| 2016-09-20 | BL-8040 in combination with Keytruda® (pembrolizumab) | pancreatic cancer | 2a | Merck&Co (USA - NJ) BiolineRx (Israel) | Cancer - Oncology |
| 2016-09-20 | noninvasive NASH diagnostic based on miRNAs | NASH (non-alcoholic steatohepatitis) | Genfit (France) | Metabolic diseases - Liver diseases - Hepatic diseases | |
| 2016-09-20 | Repatha® (evolocumab) | coronary artery disease | 3 | Amgen (USA - CA) | Cardiovascular diseases |
| 2016-09-19 | SGN-CD123A | relapsed or refractory acute myeloid leukemia | 1 | Seattle Genetics (USA - WA) | Cancer - Oncology |
| 2016-09-19 | pridopidine | motor impairment in patients with Huntington's disease | 2 | Teva Pharmaceuticals (Israel) | Neurodegenerative diseases - Rare diseases - Genetic diseases |
| 2016-09-19 | FCX-007 | recessive dystrophic epidermolysis bullosa | 1-2 | Fibrocell Technologies (USA - PA) Intrexon (USA - MD) | Rare diseases - Genetic diseases - Dermatological diseases |
| 2016-09-19 | foliglurax (PXT002331) | Parkinson's disease | 1 | Prexton Therapeutics (Switzerland) | Neurological diseases - CNS diseases |
| 2016-09-17 | siponimod (BAF312) | secondary progressive multiple sclerosis | 3 | Novartis (Switzerland) | Autoimmune diseases - Neurodegenerative diseases |
| 2016-09-16 | semaglutide | type 2 diabetes | 3 | Novo Nordisk (Denmark) | Metabolic diseases |
| 2016-09-16 | PF-06438179 (infliximab-Pfizer) | moderate to severely active rheumatoid arthritis | 3 | Pfizer (USA - NY) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2016-09-16 | ozanimod | relapsing multiple sclerosis | 2 | Celgene (USA - NJ) | Neurodegenerative diseases - Autoimmune diseases |
